Repository logo
 

Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.

Simple item page
cam.depositDate2022-07-28
cam.issuedOnline2022-09-17
cam.orpheus.counter8
cam.orpheus.successMon Sep 26 08:22:28 BST 2022 - Embargo updated*
dc.contributor.authorAllen, Isaac
dc.contributor.authorHassan, Hend
dc.contributor.authorSofianopoulou, Eleni
dc.contributor.authorEccles, Diana
dc.contributor.authorTurnbull, Clare
dc.contributor.authorTischkowitz, Marc
dc.contributor.authorPharoah, Paul
dc.contributor.authorAntoniou, Antonis C
dc.contributor.orcidAllen, Isaac [0000-0003-4640-3617]
dc.contributor.orcidTischkowitz, Marc [0000-0002-7880-0628]
dc.contributor.orcidPharoah, Paul [0000-0001-8494-732X]
dc.date.accessioned2022-07-28T23:30:36Z
dc.date.available2022-07-28T23:30:36Z
dc.date.issued2022-09-17
dc.date.updated2022-07-28T12:22:46Z
dc.description.abstractBACKGROUND: With increasing survival after cancer diagnoses, second primary cancers (SPCs) are becoming more prevalent. We investigated the incidence and site of non-breast SPC risks following male breast cancer (BC). METHODS: PubMed, Embase and Web of Science were systematically searched for studies reporting standardised incidence ratios (SIRs) for SPCs published by March 2022. Meta-analyses used the generic inverse-variance method, assuming a random-effects model. We evaluated SIRs for overall SPCs, site-specific risks, by age at BC onset, time since BC onset and geographic region. We assessed study quality using routine techniques. RESULTS: Eight population-based retrospective cohort studies were identified. SIRs ranged from 1.05 to 2.17. The summary SIR estimate was 1.27 (95% CI: 1.03-1.56, I2: 86%), and there were increased colorectal (SIR: 1.29, 95% CI: 1.03-1.61), pancreatic (SIR: 1.64, 95% CI: 1.05-2.55) and thyroid (SIR: 5.58, 95% CI: 1.04-30.05) SPC risks. When an outlying study was excluded, the summary SIR for men diagnosed with BC before age 50 was 1.50 (95% CI: 1.21-1.85), significantly higher than men diagnosed at older ages (SIR: 1.14, 95% CI: 0.98-1.33). CONCLUSIONS: Male BC survivors are at elevated risks of developing second primary colorectal, pancreatic and thyroid cancers. The estimates may assist their clinical management and guide decisions on genetic testing.
dc.description.sponsorshipCRUK Catalyst Award CanGene-CanVar (C61296/A27223).
dc.identifier.doi10.17863/CAM.87045
dc.identifier.eissn1532-1827
dc.identifier.issn0007-0920
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/339627
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.publisher.departmentDepartment of Public Health and Primary Care
dc.rightsAll Rights Reserved
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.titleRisk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.
dc.typeArticle
dcterms.dateAccepted2022-07-28
prism.publicationNameBr J Cancer
pubs.funder-project-idCancer Research UK (via Institute of Cancer Research (ICR)) (DGECATAAL)
pubs.funder-project-idNational Institute for Health Research (IS-BRC-1215-20014)
pubs.licence-display-nameApollo Repository Deposit Licence Agreement
pubs.licence-identifierapollo-deposit-licence-2-1
rioxxterms.typeJournal Article/Review
rioxxterms.versionAM
rioxxterms.versionofrecord10.1038/s41416-022-01940-1

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Combined version for Apollo.pdf
Size:
700.39 KB
Format:
Adobe Portable Document Format
Description:
Accepted version
Licence
http://www.rioxx.net/licenses/all-rights-reserved
Download

Collections

Cambridge University Research Outputs